https://www.bluerocktx.com/life-at-bluerock-career-journeys-with-patty-sachamitr/ 2023-06-26T18:08:00+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Patty-Sachamitr-Ph.D-3.jpg https://www.bluerocktx.com/wp-content/uploads/2023/06/Patty-Sachamitr-Ph.D_quote-1.jpg https://www.bluerocktx.com/life-at-bluerock-carlos-paladini/ 2023-06-26T18:08:54+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Carlos-Antonio-Paladini-3.jpg https://www.bluerocktx.com/wp-content/uploads/2023/06/Carlos-Antonio-Paladini_quote-1.jpg https://www.bluerocktx.com/life-at-bluerock-jim-kim/ 2023-06-26T18:09:12+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Jim-Kim-3.jpg https://www.bluerocktx.com/wp-content/uploads/2023/06/Jim-Kim_quote-1.jpg https://www.bluerocktx.com/human-embryonic-stem-cell-derived-oligodendrocyte-progenitors-remyelinate-the-brain-and-rescue-behavioral-deficits-following-radiation/ 2023-06-26T18:11:10+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Cellstemcell-2.jpg https://www.bluerocktx.com/cell-therapies-for-parkinsons-disease/ 2023-06-26T18:11:27+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/CTS-2.jpg https://www.bluerocktx.com/umbilical-cord-blood-derived-t-regulatory-cells-to-prevent-gvhd-kinetics-toxicity-profile-and-clinical-effect/ 2023-06-26T18:11:43+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/blood-2.jpg https://www.bluerocktx.com/genetically-engineered-macrophages-a-potential-platform-for-cancer-immunotherapy/ 2023-06-26T18:11:55+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/download.jpeg https://www.bluerocktx.com/hla-e-expressing-pluripotent-stem-cells-escape-allogeneic-responses-and-lysis-by-nk-cells/ 2023-06-26T18:12:07+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/nature_biotech-2.jpg https://www.bluerocktx.com/human-pluripotent-stem-cell-derived-atrial-and-ventricular-cardiomyocytes-develop-from-distinct-mesoderm-populations/ 2023-06-26T18:12:19+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Cellstemcell-2.jpg https://www.bluerocktx.com/human-pluripotent-stem-cells-prospects-and-challenges-as-a-source-of-cardiomyocytes-for-in-vitro-modeling-and-cell-based-cardiac-repair/ 2023-06-26T18:12:34+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/ADDR-2.jpg https://www.bluerocktx.com/preclinical-efficacy-and-safety-of-a-human-embryonic-stem-cell-derived-midbrain-dopamine-progenitor-product-msk-da01/ 2023-06-26T18:12:46+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Cellstemcell-2.jpg https://www.bluerocktx.com/biphasic-activation-of-wnt-signaling-facilitates-the-derivation-of-midbrain-dopamine-neurons-from-hescs-for-translational-use/ 2023-06-26T18:13:01+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Cellstemcell-2.jpg https://www.bluerocktx.com/generation-of-mature-compact-ventricular-cardiomyocytes-from-human-pluripotent-stem-cells/ 2023-06-26T18:14:53+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/nature-2.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-incorporate-wearable-and-invisible-contactless-digital-health-technologies-from-rune-labs-and-emerald-innovations-in-parkinsons-disease-clinical-trial/ 2023-06-26T18:30:24+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bayers-bluerock-therapeutics-establishes-european-site-for-cell-therapy-innovation/ 2023-06-26T18:30:40+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-completion-of-enrollment-of-phase-1-trial-in-patients-with-parkinsons-disease/ 2023-06-26T18:30:55+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-first-patient-dosed-in-canada-in-phase-1-trial-in-patients-with-advanced-parkinsons-disease/ 2023-06-26T18:31:06+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-closeout-of-first-cohort-in-phase-1-trial-in-patients-with-advanced-parkinsons-disease/ 2023-06-26T18:31:21+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-new-board-chair-new-president-and-ceo/ 2023-06-26T18:31:33+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease/ 2023-06-26T18:31:49+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-first-patient-dosed-with-da01-in-phase-1-study-in-patients-with-advanced-parkinsons-disease/ 2023-06-26T18:31:59+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/senti-bio-and-bluerock-therapeutics-enter-collaboration-to-develop-gene-circuit-engineered-cell-therapies-for-regenerative-medicine/ 2023-06-26T18:32:09+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-fujifilm-cellular-dynamics-and-opsis-therapeutics-enter-into-a-strategic-rd-alliance-to-discover-and-develop-cell-therapies-for-eye-diseases/ 2023-06-26T18:32:21+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-receives-permission-from-health-canada-for-da01-trial-in-parkinsons-disease/ 2023-06-26T18:32:31+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-in-collaboration-with-memorial-sloan-kettering-cancer-center-receives-ind-clearance-for-da01-in-parkinsons-disease/ 2023-06-26T18:32:41+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-appoints-seth-ettenberg-ph-d-chief-scientific-officer/ 2023-06-26T18:32:53+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/ncardia-and-bluerock-therapeutics-announce-collaboration-agreement-and-licensing-of-process-development-technologies-for-the-manufacture-of-ipsc-derived-cardiomyocytes/ 2023-06-26T18:33:06+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-present-at-2019-cell-gene-meeting-on-the-mesa/ 2023-06-26T18:33:18+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bayer-acquires-bluerock-therapeutics-to-build-leading-position-in-cell-therapy/ 2023-06-26T18:33:32+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-participate-at-upcoming-conferences-2/ 2023-06-26T18:33:42+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-present-at-2019-cell-gene-meeting-on-the-mediterranean/ 2023-06-26T18:33:53+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/editas-medicine-and-bluerock-therapeutics-enter-strategic-research-collaboration-and-cross-licensing-agreement-to-combine-genome-editing-and-cell-therapy/ 2023-06-26T18:34:02+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer/ 2023-06-26T18:34:13+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-present-at-cowen-and-company-39th-annual-health-care-conference/ 2023-06-26T18:35:47+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-establishes-key-partnerships-with-leading-experts-in-autoimmune-disease/ 2023-06-26T18:36:02+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-present-at-the-37th-annual-jp-morgan-healthcare-conference/ 2023-06-26T18:36:14+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-strengthens-collaboration-with-the-mcewen-stem-cell-institute/ 2023-06-26T18:36:28+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-appoints-min-wang-j-d-ph-d-as-chief-legal-and-administrative-officer/ 2023-06-26T18:36:41+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-participate-at-upcoming-conferences/ 2023-06-26T18:36:52+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-president-and-ceo-emile-nuwaysir-elected-to-serve-as-vice-chairman-of-the-alliance-for-regenerative-medicine/ 2023-06-26T18:37:04+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-to-present-at-2018-cell-gene-meeting-on-the-mesa/ 2023-06-26T18:37:14+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-appoints-shane-kovacs-as-chief-business-and-financial-officer/ 2023-06-26T18:37:26+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-establishes-rd-site-in-new-york-city-and-formalizes-collaboration-with-memorial-sloan-kettering-cancer-center/ 2023-06-26T18:37:36+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-appointment-of-derek-hei-ph-d-as-senior-vice-president-manufacturing-quality-and-regulatory/ 2023-06-26T18:37:47+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-appointment-of-its-ceo-and-president-to-the-alliance-for-regenerative-medicine-2018-executive-committee-and-board-of-directors/ 2023-06-26T18:37:59+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-establishes-corporate-headquarters-in-cambridge-massachusetts-and-bolsters-team-to-support-rapid-growth-and-development/ 2023-06-26T18:38:08+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-and-universal-cells-enter-collaboration-and-license-agreement-to-generate-gene-edited-ips-cell-lines/ 2023-06-26T18:38:18+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-expands-toronto-presence-with-rd-and-manufacturing-hub-appoints-key-rd-leadership/ 2023-06-26T18:38:27+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-key-members-of-executive-team/ 2023-06-26T18:38:41+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bayer-and-versant-ventures-join-forces-to-launch-stem-cell-therapy-company-bluerock-therapeutics-with-usd-225-million-series-a-financing/ 2023-06-26T18:38:53+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/BR-Logo-Card.jpg https://www.bluerocktx.com/bluerocks-neuronal-stem-cell-therapy-for-parkinsons-disease-is-first-to-show-positive-results-in-phase-i-clinical-study/ 2023-07-11T15:41:06+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/bluerock-therapeutics-and-bit-bio-announce-collaboration-and-option-agreement-for-the-discovery-and-manufacture-of-regulatory-t-cell-treg-based-therapies/ 2023-09-29T19:22:42+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/08/BRT-WEB-BITBIO_resized.jpg https://www.bluerocktx.com/in-vitro-matured-human-pluripotent-stem-cell-derived-cardiomyocytes-form-grafts-with-enhanced-structure-and-function-in-injured-hearts/ 2023-12-15T18:36:50+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Circulation-2-e1702665402892.jpg https://www.bluerocktx.com/just-one-question-podcast-s3-e6-biotech-expert-seth-and-nick-discuss-revolutionary-regenerative-medicine-treatments/ 2024-01-23T18:13:15+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/12/b49cbe86cb411762753e730c58953bb88ad958a9d657212c074729b6f04e5463.jpg https://www.bluerocktx.com/the-stem-cell-podcast-ep-228-developing-regenerative-medicines-featuring-dr-stefan-irion/ 2024-01-23T18:14:51+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/10/dr-stefan-orion.png https://www.bluerocktx.com/the-future-of-ipscs-with-bluerock-therapeutics-ceo-seth-ettenberg/ 2024-01-23T18:16:40+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/12/sddefault.jpg https://www.bluerocktx.com/bluerock-therapeutics-and-foundation-fighting-blindness-announce-collaboration-to-expand-the-uni-rare-natural-history-study-of-patients-living-with-inherited-retinal-diseases/ 2024-04-11T15:17:04+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/03/PR-WEB-FFB.jpg https://www.bluerocktx.com/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics/ 2024-04-11T15:17:30+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/01/WEBPART-OPSIS-ANNOUNCE.jpg https://www.bluerocktx.com/bluerocks-phase-i-study-with-bemdaneprocel-in-patients-with-parkinsons-disease-meets-primary-endpoint/ 2024-04-11T15:18:22+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial/ 2024-05-16T22:35:50+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/04/23_12_CGPodcast_1280x720_Ep74.jpg https://www.bluerocktx.com/headlines-of-the-future-podcast-the-future-of-cell-and-gene-therapies/ 2024-06-21T14:39:46+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/11/podcast_the-future-of-cell-and-gene.jpg https://www.bluerocktx.com/bluerock-therapeutics-phase-i-clinical-trial-for-parkinsons-disease-continues-to-show-positive-trends-at-18-months/ 2024-07-17T19:30:14+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/bluerock-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease-cell-therapy-candidate-bemdaneprocel/ 2024-07-22T21:24:57+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-fda-clearance-of-ind-application-for-investigational-ipsc-derived-cell-therapy-opct-001-for-the-treatment-of-primary-photoreceptor-diseases/ 2024-09-03T11:30:50+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/08/BRTX_NEWS.png https://www.bluerocktx.com/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses/ 2024-09-17T13:44:03+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/nature-2.jpg https://www.bluerocktx.com/bluerock-therapeutics-investigational-cell-therapy-bemdaneprocel-for-parkinsons-disease/ 2024-09-27T12:40:15+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/a-strategy-to-compare-single-cell-rna-sequencing-data-sets-provides-phenotypic-insight-into-cellular-heterogeneity-underlying-biological-similarities-and-differences-between-samples/ 2024-10-08T14:01:40+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/10/BIOINFORMATICSBIOLOGYINSIGHTS.png https://www.bluerocktx.com/bluerock-therapeutics-advances-investigational-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-to-registrational-phase-iii-clinical-trial/ 2025-01-13T13:00:57+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/bluerock-therapeutics-receives-fda-fast-track-designation-for-opct-001-for-the-treatment-of-primary-photoreceptor-diseases/ 2025-03-27T19:40:40+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/bluerock-therapeutics-announces-publication-in-nature-of-18-month-data-from-phase-1-clinical-trial-for-bemdaneprocel-an-investigational-cell-therapy-for-parkinsons-disease/ 2025-04-16T15:22:39+00:00 https://www.bluerocktx.com/wp-content/uploads/2025/04/nature-3.jpg https://www.bluerocktx.com/eye-on-the-cure-podcast/ 2025-06-05T14:32:18+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/03/PR-WEB-FFB.jpg https://www.bluerocktx.com/wp-content/uploads/2025/06/FFB_Podcast_Lenore.jpg https://www.bluerocktx.com/forging-the-future-of-cell-therapy-bayer-and-bluerocks-unique-journey/ 2025-06-05T14:32:39+00:00 https://www.bluerocktx.com/wp-content/uploads/2025/06/FIERCE-BIOTECH-NEWS.png https://www.bluerocktx.com/bluerock-therapeutics-announces-first-patient-receives-investigational-therapy-in-phase-1-2a-clinical-trial-of-opct-001-for-the-treatment-of-primary-photoreceptor-diseases/ 2025-07-08T11:00:10+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/first-parkinsons-disease-patient-treated-in-bluerocks-pivotal-phase-iii-trial-of-investigational-cell-therapy-bemdaneprocel/ 2025-09-22T10:00:58+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/08/BRTX_NEWS.png https://www.bluerocktx.com/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease/ 2025-11-04T19:15:21+00:00 https://www.bluerocktx.com/wp-content/uploads/2023/06/Bayer_BR2.jpg https://www.bluerocktx.com/how-new-modalities-could-evolve-the-treatment-of-parkinsons-disease/ 2025-11-05T20:38:31+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/11/icon1.png https://www.bluerocktx.com/cell-therapy-and-vision-loss-a-primer-on-primary-photoreceptor-diseases/ 2025-11-05T20:38:53+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/11/icon2.png https://www.bluerocktx.com/wp-content/uploads/2024/01/eye-side-view-1539x1641-1-1.jpg https://www.bluerocktx.com/wp-content/uploads/2024/11/Inherited-Retinal-Diseases-Graphic-2.png https://www.bluerocktx.com/retinitis-pigmentosa-in-perspective-an-interview-with-charles-edouard-catherine/ 2025-11-05T20:39:14+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/10/icon6.png https://www.bluerocktx.com/parkinsons-in-perspective-an-interview-with-vikas-chinnan/ 2025-11-05T20:39:40+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/10/icon5.png https://www.bluerocktx.com/bluerock-therapeutics-investigative-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-receives-pioneering-regenerative-medical-product-designation-in-japan/ 2025-12-17T11:00:55+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/08/BRTX_NEWS.png https://www.bluerocktx.com/fda-grants-orphan-drug-designation-to-bluerock-therapeutics-investigational-cell-therapy-opct-001/ 2026-01-22T10:00:21+00:00 https://www.bluerocktx.com/wp-content/uploads/2024/08/BRTX_NEWS.png